Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Novel fusion proteins for the antigen-specific staining and elimination of B cell receptor-positive cell populations demonstrated by a tetanus toxoid fragment C (TTC) model antigen

: Klose, D.; Saunders, U.; Barth, S.; Fischer, R.; Jacobi, A.M.; Nachreiner, T.

Volltext (PDF; )

BMC biotechnology. Online journal 16 (2016), Art. 18, 11 S.
ISSN: 1472-6750
Deutsche Forschungsgemeinschaft DFG
NA 1063/1-1
Deutsche Forschungsgemeinschaft DFG
JA 2003/2-1
Zeitschriftenaufsatz, Elektronische Publikation
Fraunhofer IME ()

Background: In an earlier study we developed a unique strategy allowing us to specifically eliminate antigen-specific murine B cells via their distinct B cell receptors using a new class of fusion proteins. In the present work we elaborated our idea to demonstrate the feasibility of specifically addressing and eliminating human memory B cells.
Results: The present study reveals efficient adaptation of the general approach to selectively target and eradicate human memory B cells. In order to demonstrate the feasibility we engineered a fusion protein following the principle of recombinant immunotoxins by combining a model antigen (tetanus toxoid fragment C, TTC) for B cell receptor targeting and a truncated version of Pseudomonas aeruginosa exotoxin A (ETA') to induce apoptosis after cellular uptake. The TTC-ETA' fusion protein not only selectively bound to a TTC-reactive murine B cell hybridoma cell line in vitro but also to freshly isolated human memory B cells from immunized donors ex vivo. Specific toxicity was confirmed on an antigen-specific population of human CD27(+) memory B cells.
Conclusions: This protein engineering strategy can be used as a generalized platform approach for the construction of therapeutic fusion proteins with disease-relevant antigens as B cell receptor-binding domains, offering a promising approach for the specific depletion of autoreactive B-lymphocytes in B cell-driven autoimmune diseases.